TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35916679

Group type: EXPERIMENTAL
Intervention: VERDICT MRI analysis
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: mpMRI-derived apparent diffusion coefficient (ADC)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen density (PSAD)
Number of subjects: 303
Study: 35916685

Group type: EXPERIMENTAL
Intervention: Compensated cirrhosis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HRS-AKI
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 87
Study: 35916686

Group type: EXPERIMENTAL
Intervention: Indoor air quality monitor and home spirometer to measure VOCs and PM
Number of subjects: 50
Study: 35916707

Group type: EXPERIMENTAL
Intervention: iQuit Mindfully text messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness videoconference groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of iQuit Mindfully text messages and mindfulness videoconference groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: No iQuit Mindfully text messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mindfulness videoconference groups
Number of subjects: 0
Study: 35916981

Group type: EXPERIMENTAL
Intervention: Catheter drainage
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting catheter-drainage failure
Number of subjects: 72
Study: 35917057

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35917174

Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program (SEP)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Home-Based Structured Exercise Program (HSEP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Walk Advice (WA)
Number of subjects: 166
Study: 35917659

Group type: EXPERIMENTAL
Intervention: Co-occurring anxiety symptoms
Number of subjects: 216

Group type: COMPARATOR
Intervention: Hostility/anger
Number of subjects: 216

Group type: COMPARATOR
Intervention: Trait positive affect
Number of subjects: 216
Study: 35917778

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35917829

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394
Study: 35918160

Group type: EXPERIMENTAL
Intervention: β-amyloid positivity
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Cortical thickness in medial temporal lobe structures
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Neuroinflammation
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS) assessment
Number of subjects: 921
Study: 35918190

Group type: EXPERIMENTAL
Intervention: Amnioinfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention observational expectant management
Number of subjects: 0
Study: 35918231

Group type: EXPERIMENTAL
Intervention: AYAs reported navigating openness and closedness about LFS in their families, which varied by LFS topic, relationship, disease trajectory, and developmental phase.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AYAs reported experiencing LFS family communication challenges that disrupted their psychosocial well-being.
Number of subjects: 38
Study: 35918246

Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by EAT-Lancet Diet Index, ELD-I)
Number of subjects: 62382

Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by ELD-I) among low drinkers
Number of subjects: 62382

Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by ELD-I) among females
Number of subjects: 62382
Study: 35918666

Group type: EXPERIMENTAL
Intervention: No-cost contraception (April 2016-March 2017)
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Control period with no reduction in cost for the contraceptive implant, reduced price for hormonal IUD, sliding scale for copper IUD (September 2015-March 2016)
Number of subjects: 1029
Study: 35918683

Group type: EXPERIMENTAL
Intervention: New light rail transit (LRT) line
Number of subjects: 0
Study: 35918685

Group type: EXPERIMENTAL
Intervention: Post-mortem magnetic resonance imaging with computed tomography-guided biopsy (Virtopsy®)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Computed tomography-guided tissue sampling
Number of subjects: 101
Study: 35918703

Group type: EXPERIMENTAL
Intervention: Multi-level hypertension control program including a hypertension patient registry, performance and quality reporting, simplified treatment guidelines, access to essential medicines, team-based care, health coaching, and home blood pressure monitoring.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control phase of sequential registration and empanelment of hypertensive patients at participating primary healthcare centers.
Number of subjects: 60
Study: 35918719

Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment including respiratory assessment, muscular evaluation, psychopathological evaluation, and quality of life
Number of subjects: 62
Study: 35918722

Group type: EXPERIMENTAL
Intervention: Tuberculin skin testing (TST) or interferon gamma release assay (IGRA) for TB infection (TBI) followed by chest X-Ray (CXR) to rule out TB disease (TBD) if positive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GeneXpert (GX) replaces CXR after TST or IGRA for TBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TBI testing, CXR for all; if CXR is normal, TPT is recommended
Number of subjects: 0
Study: 35918734

Group type: EXPERIMENTAL
Intervention: Short-term educational intervention on complementary feeding (CF) provided by community health workers (CHWs).
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Short-term educational intervention on complementary feeding (CF).
Number of subjects: 360

Group type: COMPARATOR
Intervention: Existing healthcare services (comparison group).
Number of subjects: 360
Study: 35918743

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) injections, mean number of injections by Month 12: 3.7 ± 1.8 (treatment-naïve), 4.0 ± 2.2 (previously treated).
Number of subjects: 258
Study: 35918757

Group type: EXPERIMENTAL
Intervention: Vestibular therapy (VT) for 8 weeks, ~25-min office sessions with a vestibular therapist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active control therapy for 8 weeks
Number of subjects: 100
Study: 35919026

Group type: EXPERIMENTAL
Intervention: Deep learning model for locating the interscalene brachial plexus in ultrasound images
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Nonexpert anaesthesiologists
Number of subjects: 1126
Study: 35919065

Group type: EXPERIMENTAL
Intervention: Ultra-low dose computed tomography (ULD-CT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Digital radiography
Number of subjects: 76
Study: 35919265

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 94
Study: 35919268

Group type: EXPERIMENTAL
Intervention: Low-frequency intermittent fasting regimen
Number of subjects: 0
Study: 35919345

Group type: EXPERIMENTAL
Intervention: Frailty assessed by CFS (frail group)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Pre-frail assessed by CFS
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Robust assessed by CFS
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Frailty assessed by Fried criteria (frail group)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Pre-frail assessed by Fried criteria
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Robust assessed by Fried criteria
Number of subjects: 263
Study: 35919538

Group type: EXPERIMENTAL
Intervention: Urinary CCL14 cutoff of 1.3 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary CCL14 cutoff of 13 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCL14 concentration between 1.3 and 13 ng/ml
Number of subjects: 0
Study: 35919662

Group type: EXPERIMENTAL
Intervention: Pictorial risk information (graphical representation of atherosclerosis)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group (without intervention)
Number of subjects: 3000
Study: 35919766

Group type: EXPERIMENTAL
Intervention: Tight Control (TC) management with TNFi dose changes informed by biochemical markers of inflammation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight Control (TC) management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 0
Study: 35920161

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 1279
Study: 35920743

Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg)
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301
Study: 35920783

Group type: EXPERIMENTAL
Intervention: NC-6300 (Nanoparticle Epirubicin) at a dose of 150 mg/m2 intravenously (IV) once every 3 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NC-6300 (Nanoparticle Epirubicin)
Number of subjects: 10
Study: 35920839

Group type: EXPERIMENTAL
Intervention: Decision Support System
Number of subjects: 0
Study: 35920968

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 100
Study: 35921139

Group type: EXPERIMENTAL
Intervention: Secure Messaging for Medication Reconciliation Tool (SMMRT)
Number of subjects: 20
Study: 35921449

Group type: EXPERIMENTAL
Intervention: L9LS administered intravenously or subcutaneously at doses of 1 mg, 5 mg, or 20 mg per kilogram of body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (not specified)
Number of subjects: 0
Study: 35921541

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ibrutinib added to Venetoclax
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ibrutinib continued
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Venetoclax ± Ibrutinib
Number of subjects: 38
Study: 35921627

Group type: EXPERIMENTAL
Intervention: Training with simulated patients
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Both groups (simulated patient and control)
Number of subjects: 1113
Study: 35921685

Group type: EXPERIMENTAL
Intervention: eHealth system alerts for high risk of ED visits
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: eHealth system usability
Number of subjects: 206
Study: 35921693

Group type: EXPERIMENTAL
Intervention: Cognitive development assessment using Bayley Scales at 6, 12, 24, and 36 months
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Motor development assessment using Bayley Scales at 6, 12, 24, and 36 months
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Cognitive, motor and behavioral outcomes using Movement Assessment Battery for Children and Child Behavior Checklist for Ages 1.5-5 at 4 years of age
Number of subjects: 580
Study: 35921817

Group type: EXPERIMENTAL
Intervention: CD24Fc treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivation of the CD24-Siglec-E pathway
Number of subjects: 0
Study: 35922062

Group type: EXPERIMENTAL
Intervention: eSkinHealth app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 35922667

Group type: EXPERIMENTAL
Intervention: BCL11A enhancer-edited, autologous, hematopoietic stem and progenitor cells
Number of subjects: 2
Study: 35922770

Group type: EXPERIMENTAL
Intervention: Data driven model of Achilles tendon health
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Five uncorrelated factors identified: biopsychosocial, lower extremity function, body size, load tolerance, tendon structure
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Measurement Information System
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Counter-movement jump height
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pain with hopping
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tendon cross-sectional area
Number of subjects: 99
Study: 35922777

Group type: EXPERIMENTAL
Intervention: Chronotype and chrononutrition interventions
Number of subjects: 166
Study: 35922793

Group type: EXPERIMENTAL
Intervention: Maternal food preoccupation and responsiveness
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Pregnancy ultra-processed food intake (% of energy intake)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 458
Study: 35922819

Group type: EXPERIMENTAL
Intervention: SMC drugs only
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SMC drugs and praziquantel
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SMC drugs and albendazole and praziquantel
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 600
Study: 35922861

Group type: EXPERIMENTAL
Intervention: Eltanexor 10 mg, administered on days 1-5 each week of a 28-day cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eltanexor 20 mg, administered on days 1-5 each week of a 28-day cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eltanexor (both doses combined)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eltanexor (efficacy-evaluable patients)
Number of subjects: 20
Study: 35922860

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 4994

Group type: COMPARATOR
Intervention: No corticosteroids
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy duration
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Bacterial co-infection at admission
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: ICU-acquired infections (ICU-AI)
Number of subjects: 4994
Study: 35922868

Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial sheet transplantation
Number of subjects: 6
Study: 35923658

Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - high engagement group
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - moderate engagement group
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Aripiprazole tablets with sensor (AS) - discontinued group
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Participants who completed 3 months of the study with higher AS engagement
Number of subjects: 277
Study: 35923787

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR-positive children
Number of subjects: 162

Group type: COMPARATOR
Intervention: Age-matched PCR-negative controls
Number of subjects: 162
Study: 35923824

Group type: EXPERIMENTAL
Intervention: ACCOMPAGNE program (educational program for patient/natural caregiver dyads)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional approaches (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACCOMPAGNE program
Number of subjects: 0
Study: 35923923

Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab (H), pertuzumab (P), and paclitaxel for 16 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: D8 biopsies
Number of subjects: 23
Study: 35923926

Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB) + tissue testing (TT) using Guardant360™ assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue testing (TT) alone
Number of subjects: 0
Study: 35923928

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 77
Study: 35924212

Group type: EXPERIMENTAL
Intervention: Singing to a 14-min video led by a voice expert
Number of subjects: 60
Study: 35924481

Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Potential drivers (PDs) identified using ECGI mapping
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Burden of rotational PDs, rotational stability, and burden of PDs occurring at the pulmonary veins and posterior wall
Number of subjects: 100
Study: 35924778

Group type: EXPERIMENTAL
Intervention: Higher suPAR levels
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Higher D-dimer levels
Number of subjects: 1960
Study: 35924841

Group type: EXPERIMENTAL
Intervention: Urine CrAg testing
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Fingerprick whole blood CrAg testing
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Both POC CrAg tests
Number of subjects: 1333
Study: 35925037

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 3124
Study: 35925040

Group type: EXPERIMENTAL
Intervention: Person-centred, theory-based oral health education program
Number of subjects: 19
Study: 35925555

Group type: EXPERIMENTAL
Intervention: Fexinidazole 1200 mg/day for 2 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fexinidazole 1800 mg/day for 2 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fexinidazole (various regimens)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 35925583

Group type: EXPERIMENTAL
Intervention: Carriers of rare CFH variants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rare variant P258L
Number of subjects: 23
Study: 35925612

Group type: EXPERIMENTAL
Intervention: Implementation of the Criteria of Good Disease Management of Diabetes established by the Swiss Society of Endocrinology and Diabetology (SSED)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Implementation of the SSED criteria
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: SSED criteria implementation
Number of subjects: 727
Study: 35925686

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for acute VTE
Number of subjects: 98
Study: 35925717

Group type: EXPERIMENTAL
Intervention: We-talk in caregivers of children with rare or undiagnosed diseases
Number of subjects: 0

Group type: COMPARATOR
Intervention: We-talk in caregivers of typically developing children
Number of subjects: 0
Study: 35925831

Group type: EXPERIMENTAL
Intervention: Implanting new leads in patients with dislodged leads
Number of subjects: 20683

Group type: COMPARATOR
Intervention: Lead dislodgement events
Number of subjects: 20683

Group type: COMPARATOR
Intervention: Passive fixation type leads
Number of subjects: 20683

Group type: COMPARATOR
Intervention: Female sex and higher body mass index
Number of subjects: 20683
Study: 35925981

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation program
Number of subjects: 300
Study: 35926075

Group type: EXPERIMENTAL
Intervention: 3D camera guidance (camera on)
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Laser-guided positioning (camera off)
Number of subjects: 3118
Study: 35926201

Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy
Number of subjects: 10572

Group type: COMPARATOR
Intervention: Total hysterectomy
Number of subjects: 10572
Study: 35926204

Group type: EXPERIMENTAL
Intervention: IV ketamine 200-500 micrograms/kg IV over 2 minutes, repeated every 5 minutes until appropriate analgesia was achieved
Number of subjects: 110

Group type: COMPARATOR
Intervention: IV fentanyl 0.5-1 micrograms/kg IV over 2 minutes, repeated every 5 minutes until appropriate analgesia was achieved
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IV ketamine
Number of subjects: 110

Group type: COMPARATOR
Intervention: IV fentanyl
Number of subjects: 110
Study: 35926241

Group type: EXPERIMENTAL
Intervention: ctDNA alteration level (level 1: no alterations)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: ctle-RECIST based on ctDNA alteration level
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: dual-DCR group
Number of subjects: 223
Study: 35926332

Group type: EXPERIMENTAL
Intervention: Total testosterone levels
Number of subjects: 996

Group type: COMPARATOR
Intervention: Behavioral weight loss intervention
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Estradiol levels
Number of subjects: 996
Study: 35926375

Group type: EXPERIMENTAL
Intervention: GCA/PMR
Number of subjects: 674

Group type: COMPARATOR
Intervention: RA
Number of subjects: 674
Study: 35926895

Group type: EXPERIMENTAL
Intervention: GLS
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GWI
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GCW
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GWI and GCW
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MWIs
Number of subjects: 136
Study: 35926941

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35926961

Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients older than 60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with less than 5 years of evolution
Number of subjects: 0
Study: 35926993

Group type: EXPERIMENTAL
Intervention: Usual care for rotator cuff repair (RCR)
Number of subjects: 141
Study: 35927040

Group type: EXPERIMENTAL
Intervention: Virtual Smax ablation (V-Smax)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Empirical ablation (E-ABL)
Number of subjects: 178
Study: 35927208

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 35927231

Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (UMSCs) infusion
Number of subjects: 17
Study: 35927368

Group type: EXPERIMENTAL
Intervention: Full-length double-stranded DNA (flDNA)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pregenomic RNA (pgRNA)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Spliced1 RNA (sp1RNA)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Spliced-derived DNA (defDNA)
Number of subjects: 162
Study: 35927485

Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding (n=13)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Any human milk feeding
Number of subjects: 243

Group type: COMPARATOR
Intervention: Formula feeding (n=230)
Number of subjects: 243
Study: 35927539

Group type: EXPERIMENTAL
Intervention: Finger plethysmography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transthoracic echocardiography
Number of subjects: 100